(Q44204184)

30 November 2017

title

Late-starter sites in randomized controlled trials (English)

1 reference

30 November 2017

2

John P A Ioannidis

1 reference

30 November 2017

Anna-Bettina Haidich

1

1 reference

30 November 2017

publication date

1 May 2003

1 reference

Journal of Clinical Epidemiology

30 November 2017

published in

1 reference

30 November 2017

volume

56

1 reference

30 November 2017

issue

5

1 reference

30 November 2017

page(s)

408-415

1 reference

Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Performance evaluation in multicenter clinical trials: development of a model by the AIDS Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Enrollment in clinical trials: institutional factors affecting enrollment in the cardiac arrhythmia suppression trial (CAST)

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Designing a cost-effective clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Recruitment experience in clinical trials: literature summary and annotated bibliography

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Patterns of patient enrollment in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Effect of early patient enrollment on the time to completion and publication of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Lessons learned from enrollment in the BEST study—A multicenter, randomized trial of group psychosocial support in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Recruitment in the Coronary Drug Project and the Aspirin Myocardial Infarction Study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Recruitment experience in the Aspirin Myocardial Infarction Study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Recruitment of participants for the multiple risk factor intervention trial (MRFIT)

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Entry into clinical trials in breast cancer: the importance of specialist teams. Scottish Breast Cancer Focus Group and Scottish Cancer Therapy Network

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Relationship between event rates and treatment effects in clinical site differences within multicenter trials: an example from primary Pneumocystis carinii prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Adjustments for center in multicenter studies: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Size of cancer clinical trials and stopping rules

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Some adaptive strategies for inadequate sample acquisition in veterans administration cooperative clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Planning patient recruitment: fantasy and reality

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

Determinants of patient recruitment in a multicenter clinical trials group: trends, seasonality and the effect of large studies

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900032-5

7 January 2021

10.1016/S0895-4356(03)00032-5

Identifiers

DOI

1 reference

30 November 2017

1 reference